Parnell Pharmaceuticals Holdings (NASDAQ: PARN) and NephroGenex (NASDAQ:NRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.
This table compares Parnell Pharmaceuticals Holdings and NephroGenex’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Parnell Pharmaceuticals Holdings||-151.70%||-134.28%||-53.60%|
Insider & Institutional Ownership
16.9% of Parnell Pharmaceuticals Holdings shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Parnell Pharmaceuticals Holdings and NephroGenex’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Parnell Pharmaceuticals Holdings||N/A||N/A||N/A||($1.29)||-0.53|
Parnell Pharmaceuticals Holdings is trading at a lower price-to-earnings ratio than NephroGenex, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Parnell Pharmaceuticals Holdings has a beta of 0.33, meaning that its share price is 67% less volatile than the S&P 500. Comparatively, NephroGenex has a beta of -0.98, meaning that its share price is 198% less volatile than the S&P 500.
This is a breakdown of recent ratings and price targets for Parnell Pharmaceuticals Holdings and NephroGenex, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Parnell Pharmaceuticals Holdings||0||0||0||0||N/A|
NephroGenex has a consensus price target of $17.50, indicating a potential upside of 12,400.00%. Given NephroGenex’s higher probable upside, analysts clearly believe NephroGenex is more favorable than Parnell Pharmaceuticals Holdings.
Parnell Pharmaceuticals Holdings beats NephroGenex on 5 of the 8 factors compared between the two stocks.
Parnell Pharmaceuticals Holdings Company Profile
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
NephroGenex Company Profile
NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.
Receive News & Ratings for Parnell Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals Holdings Ltd and related companies with MarketBeat.com's FREE daily email newsletter.